Company

Syndesi Therapeutics SA

Syndesi Therapeutics develops SV2A modulators aimed at improving cognition in Alzheimer's, other dementias and schizophrenia-related impairment.

About

Based in Louvain-la-Neuve, Belgium and founded in 2018, Syndesi Therapeutics SA is a biotechnology company developing SV2A modulators. The drugs aim to improve cognition in conditions such as Alzheimer's disease, other dementias and cognitive impairment associated with schizophrenia. In March 2022, AbbVie acquired Syndesi from Novo Holdings, Fountain Healthcare, Johnson & Johnson Innovation and others for USD 1 billion in total deal value, including USD 130 million upfront. As of May 2023, Jonathan Savidge is CEO.

2Funding rounds

5Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in